CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Avastin for Platinum-Resistant Ovarian Cancer – Details

Project Number PC0066-000
Brand Name Avastin
Generic Name Bevacizumab
Strength 25mg/mL
Tumour Type Gynecology
Indication Platinum-Resistant Ovarian Cancer
Funding Request In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Review Status Complete
Pre Noc Submission No
NOC Date September 25, 2015
Manufacturer Hoffmann-La -Roche Limited
Sponsor Hoffmann-La -Roche Limited
Submission Date October 29, 2015
Submission Deemed Complete November 5, 2015
Submission Type Initial
Prioritization Requested Requested and Not Granted
Stakeholder Input Deadline ‡ November 12, 2015
Check-point meeting December 16, 2015
pERC Meeting February 18, 2016
Initial Recommendation Issued March 3, 2016
Feedback Deadline ‡ March 17, 2016
pERC Reconsideration Meeting April 21, 2016
Final Recommendation Issued May 5, 2016
Notification to Implement Issued May 20, 2016
Therapeutic Area Platinum Resistant Ovarian Cancer
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.